 Bleomycin
"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 3 | 5 | | 2012 | 3 | 3 | 6 | | 2013 | 1 | 1 | 2 | | 2014 | 0 | 4 | 4 | | 2015 | 1 | 2 | 3 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 5 | 6 | | 2018 | 5 | 6 | 11 | | 2019 | 2 | 9 | 11 | | 2020 | 2 | 7 | 9 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 3 | 4 | | 2025 | 3 | 2 | 5 | | 2026 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
-
Sakamachi Y, Wiley E, Trempus CS, Jacobs H, Solis A, Johnson CG, Meng X, Hussain S, Roselli A, Lipinski JH, O'Dwyer DN, Randall TA, Malphurs J, Papas B, Wu BG, Li Y, Kugler MC, Mehta S, Scappini E, Thomas SY, Li JL, Zhou L, Karmaus PW, Lih FB, Fessler MB, McGrath JA, Gibson K, Kass DJ, Gleiberman A, Andrianova E, Walts A, Invernizzi R, Molyneaux PL, Yang IV, Zhang Y, Kaminski N, Segal LN, Schwartz DA, Gudkov AV, Garantziotis S. Toll-like receptor 5 protects against murine lung fibrosis through reduced dysbiosis, and TLR5 deficiency is associated with human IPF. Sci Transl Med. 2026 Jun 03; 18(852):eadw1028.
-
Wang Y, Hennessy C, Dobrinskikh E, Humphries SM, Hatakka K, Ackert-Bicknell CL, Godfrey DA, Kelada SNP, Keele GR, Cardwell J, Peljto A, Clouthier DE, Yang IV, Schwartz DA. Genes, other than Muc5b, are associated with bleomycin-induced lung injury. Commun Biol. 2026 May 12; 9(1).
-
Foster DG, Javkhlan N, Black BP, Vestal BE, Riches DW, Redente EF. Pulmonary fibroblast subsets demonstrate differentially enriched signaling pathways during fibrosis resolution and repair. JCI Insight. 2026 Jul 08; 11(13).
-
Epeldegui M, Moser C, Choi Y, Borok M, Campbell TB, MacPhail P, Hosseinipour MC, Samaneka W, Nyirenda M, Kosgei J, Busakhala N, Martinez-Maza O, Krown SE. Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings. J Acquir Immune Defic Syndr. 2026 Apr 01; 101(4):416-423.
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 Mar 19; 147(12):1289-1301.
-
Signoretti C, Fatehi S, Drewes R, Cendali F, Dzieciatkowska M, D'Alessandro A, Bae Y, Gupte SA. Bleomycin-induced lung fibrosis and dysfunction is exacerbated by G6PD deficiency. Am J Physiol Lung Cell Mol Physiol. 2026 02 01; 330(2):L145-L158.
-
Kim SH, Nouws J, Ruwisch J, Woodard GA, Cooley J, Khoury J, Sun H, Doherty E, Piecychna M, Manning EP, Kang MJ, Bruscia EM, Wei H, Zhang Y, Yarovinsky TO, Hwa J, Zacharias WJ, Ingram J, Lee CG, Elias JA, Kaminski N, Redente EF, Herzog EL, Prasse A, Bucala R, Sauler M. Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor-CD74 signaling. Sci Transl Med. 2025 12 03; 17(827):eadr2277.
-
Bousamaki J, Rørbeck EA, Petersen AG, Korntner SH, Pors SE, Redente EF, Oró D, Salinas CG, Olsen RW, Simonsen U, Feigh M, Hansen HH. Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis. Physiol Rep. 2025 Sep; 13(18):e70560.
-
Brazee P, Allen N, Knipe R, Redente EF, Le Saux CJ. Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions. Semin Respir Crit Care Med. 2025 Aug; 46(4):330-346.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|